Our Bill Patalon first introduced this biotech company to you on the very first day he published his Private Briefing service, and it's been a huge winner for you since.
- This Baby Biotech Has Lots of Running Room, Thanks to This Upcoming "Super" Drug
- The NFL's Biggest Problem Could Be Pharmaceutical Cannabis' Biggest Breakthrough
- How to Find Tiny Stocks Packing Quadruple-Digit Profit Potential
- These Breakout Biotechs Are the Best of the "Best in Breed"
- Let's Buy the Real Breakout in the Soaring Tech Sector
- Get Your Hands on the World's First $1 Billion Cannabis Drug
- Our "War on Pain" Biotech Put You Up by Double Digits in Just Two Weeks
- This "Quick Doubler" Biotech Will Likely Disappoint
- Forget Allergan – Here's Pfizer's Real High-Profit Ace
- As Another Sector's Sails Lose Wind, Watch This One Barometer
- This Biotech Patent Leader Generates an 8.3% Dividend Yield
- Meet the Biotech CEO With a $30 Billion Breakthrough
- The Next Profit Breakthrough: Synthetic Biology
- Letting Biotech Companies "Patent Nature" Could Be a Huge Boon for Investors
- Three Biotech Stocks to Buy Now
- “Cyborg” Tissue Blurs the Line Between Man and Machine
America loves its football, and football fans love a big hit. For years, the National Football League prepared promotional videos showing the biggest hits from each week - videos its network associates eagerly aired to gin up even more interest in the coming week's games.
But those "big hits" were the genesis of a shameful legacy in the NFL: Concussions - and a terrifying disease called chronic traumatic encephalopathy.
CTE is a degenerative brain disease brought on by too many big concussions received over the years. CTE causes memory problems, cognitive difficulties, and, eventually, even dementia.
To be fair, CTE is also a problem among combat military personnel, hockey players, soccer players, pro fighters, and others, but the CTE story broke in the NFL.
There is no cure. In fact, it can't even be diagnosed in a living brain; a post-mortem examination is needed to even find CTE.
And it has caused plenty of deaths. Several NFL players with CTE have committed suicide; a few have committed murder. Dozens of others have surrendered what should have been a happy retirement to a lifetime of pain and mental illness.
And the NFL almost surely knew. How could it not?
The league even paid a settlement in excess of $1 billion to avoid a trial in which evidence scheduled to be presented would have suggested just how much they knew... and when they knew it.
To its credit, the modern NFL is cleaning up its act. It has changed the rules to make concussions less frequent. It's changed other rules to get players with head injuries out of games until they can pass concession-testing protocol.
But concussions will still occur, and some players will get enough concussions to get CTE.
But what if there were a cure? Even better, what if CTE could be prevented?
One company I know of is researching those very same questions. This firm is being advised by a retired NFL player with degrees from Harvard and Dartmouth.
The team aims to discover whether CTE can be cured or even prevented with cannabis.
The research is exciting - and promising. If this firm succeeds, it will do a tremendous amount of good.
Micro-cap and penny biotech stocks (those with a market cap at less than $300 million) have a reputation for being extremely speculative, volatile, and unpredictable.
But they can also deliver returns beyond your wildest expectations.
In fact, some of these companies have become legendary for minting millionaires, as they rocketed from bargain basement to stellar valuation. Others, of course, crashed and burned along the way.
In this investment niche, little is certain, but a little legwork can give you an edge when picking the winners from the also-rans.
In a moment, I'm going to show you two things I always look for when I'm researching these special stocks for my Biotech Insider Alert subscribers.
Our Chris Johnson is here with another set of "Best in Breed" breakout biotech stocks that are truly the cream of the crop.
The tech sector has been having a field day lately, and our Chris Johnson is back with his latest "Best in Breed" focus: biotech.
When it comes to biotech, Wall Street tends to overreact. Though there's no reason for it to be there, biotech is in the dog house, and investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself.
You see, there are three main reasons biotech is down: Wall Street is worried about high and rising drug prices, the impact of a possible trade war on foreign sales, and expiring patents for some older medications.
Over the last several years, for example, I've read a number of Wall Street reports about the so-called "biotech patent cliff." Simply stated, a drug falls off that "cliff" when its patent runs out and it starts facing competition from generics.
And a number of successful drugs out there are rapidly approaching their patent cliffs.
That sounds bad.
But there are good things happening in biotech, as well. In fact, what you don't hear much about is that the industry is about to bust out.
For example, I was thrilled to see a recent report from Clarivant Analytics, a research firm that works closely with industry leaders and top universities, which says a total of 12 compounds being released in 2018 could become blockbusters.
So I went through the data and found one ultimate biotech blockbuster that I think could lead the pack.
Insys Therapeutics - our "War on Pain" biotech play - has given us a profit of more than 10.7% since we recommended the stock a little less than two weeks ago.
I hope you like profits, because that's just for starters.
The U.S. Food and Drug Administration (FDA) last week approved the final "product label" for the company's new synthetic marijuana drug - which means Insys can bring this new therapy to market in August.
Investors who specialize in drug stocks are always trying to pull profits from trades based on the three-step FDA "phalanx" that up-and-coming biotechs must navigate to finally get a new drug to market.
But if you really want to cash in, commercialization is the "triggering event" that can make that happen.
And that's exactly where Insys is right now.
Stroke kills an American every four minutes - more than 525,000 individuals each year - and nearly 300,000 more fall victim to its debilitating consequences.
The onset of symptoms signal a dire emergency. According to the National Stroke Association, they can include:
- Sudden numbness or weakness of the face, arm or leg, especially on one side of the body;
- Sudden confusion, trouble speaking or understanding;
- Sudden trouble seeing or blurred vision in one or both eyes; and/or
- Sudden trouble walking, dizziness, loss of balance or coordination.
There are two types of stroke: hemorrhagic and ischemic. The first results from a ruptured blood vessel in the brain, and the other from an inadequate blood supply, usually due to a blood clot blocking an artery that feeds the brain.
The second variety, ischemic stroke, is by far the more common. Nearly nine out of 10 are of this type. And that's fortunate, because an ischemic stroke could be relatively easy to prevent - provided you see it coming.
If you had the technology to find and map arterial blockages safely, simply, and quickly, you could intervene with a relatively simple medical procedure, clear the blockage, and bring down that enormous annual incidence of stroke to a much smaller number.
Does such a technology exist?
Currently, doctors can use an ultrasound machine to detect the presence of an occlusion (blockage) or stenosis (narrowing) in a carotid or cerebral artery, but the patient then has to undergo a CT scan or MRI for more definitive information.
It's a complicated, drawn-out, and extremely expensive process, and you would think a single-step, cheaper technology might be a game changer - and represent a windfall for investors.
One micro-cap biotech in Vancouver, Canada, CVR Medical, is counting on exactly that with its new carotid stenotic scan (CSS) device.
The device is about to enter pivotal clinical trials, and after they're completed, will go to the U.S. Food and Drug Administration (FDA) for marketing approval.
The CSS could save the government up to $34 billion a year, according to the CDC, and more importantly, hundreds of thousands of lives in the United States and around the world.
That's great news for patients and their families. And it has proven a terrific opportunity for investors, too. Since the company's IPO in November 2016, the stock is already up over 90%.
But here's the thing. This device may not be the silver bullet it's cracked up to be. And the stock isn't, either.
Big-cap investors were profoundly underwhelmed when the Obama administration caused Pfizer Inc. to cancel a $150 billion buyout of another massive pharma, Allergan Plc.
Like most deal-making at this level, there was a lot at stake. Allergan has a portfolio packed with name-brand drugs with long patent lives and a robust generics business. What's more, the deal would have allowed Pfizer to relocate its headquarters to the (extremely) tax-friendly Republic of Ireland and save a ton on payments to Uncle Sam.
Now, normally when a deal like this falls through, the shares take a serious pounding, but the smart money is holding its nerve. In fact, the stock is up just over 10% year to date. That says a lot.
Those investors, along with folks who buy in right now, stand to be richly rewarded in the future.
One by one, the bubbles are bursting...
First it was the commodities bubble that blew up in mid-2014, which caused the collapse of energy and commodity stocks -they are now down between 40-80%.
It also caused the end of the corporate credit bubble in high yield bonds and bank loans over the second half of 2014 and into this year.
Most biotech stocks are growth plays, so you'll almost never find one that pays anything more than a bare bones dividend. But this company has a distinct advantage that allows it to reward its shareholders - big-time. Michael Robinson explains.
There's a deadly problem with one of the nation's major medical markets - vaccines.
The technology we use today to prevent diseases like the flu, chicken pox, and polio is hopelessly outdated.
It still relies on the delivery of a portion of the actual virus to the patient to develop immunity. Some of these agents are still grown in chicken eggs, just like they were back in the 1930s. And the vaccines themselves or their additives can still make people sick.
But what if you could develop a whole new class of vaccines that were actually safe using a synthetic DNA? Better yet, what if you could vaccinate yourself against HIV, cervical cancer, leukemia, and hepatitis?
The payoff would be tremendous...
For example, teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial. They're also growing new microorganisms that yield biofuels to be used in lieu of oil.
Trouble is, the process is so complex that it can take days to synthesize these man-made genes, usually in small batches.
Not only is it time consuming, but it requires the use of costly robots and other advanced gear. Simply stated, if someone came along with a breakthrough that greatly speeded up the development of synthetic genes, it could affect several industries at once, not to mention its own value in the market.
Allow me to introduce you to Gen9 Inc. The company is blazing a trail in the development of scalable technologies for synthesizing genes.
Now, Gen9 is a small, new dynamic company. And its potential is huge.
It was formed last summer around a unique new device that greatly speeds up the process of creating synthetic DNA.
Even better, it cuts the cost of that process by leaps and bounds.
Next June, the nine justices are expected to settle - once and for all - whether companies can patent human genes in the United States.
The Patent and Trademark Office has been issuing patents on DNA for nearly 30 years, according to Bloomberg Businessweek.
Roughly 4,000 of the 22,000 human genes now have some form of patent.
But the American Civil Liberties Union has challenged the practice in Association for Molecular Pathology v. Myriad Genetics. Now that case will go to the highest court in the country.
At heart, the legal question sounds simple: Does Myriad Genetics Inc. (NasdaqGS:MYGN) have the right to patent two genes that signal whether a woman is at higher risk of getting cancer of the breasts or ovaries?
Myriad of course did not invent or create the breast cancer predisposition genes, referred to as BRCA genes.
But it did create something called the BRACAnalysis test that looks for mutations on these genes. Those mutations are associated with much greater risks of breast and ovarian cancer.
Usually firms cannot get that kind of market protection for something that is clearly a product of nature. But in this case, Myriad has developed a process of extracting a gene that makes the resulting molecule novel and chemically different from DNA that naturally occurs in our bodies.
And, after all, it took Myriad 17 years and $500 million to develop the test. Without barriers to entry, other firms could simply come in, take advantage of all that costly effort and sell a knockoff for less money.
Even if that weren't illegal, it's obviously unfair.
Let's dig into the case and why it matters to you...
Here's why: biotech stocks have been in a stealth bull market in 2012.
In fact, the values of the 230 publicly-traded biotech companies tracked by the BioWorld Stock Report have jumped by an average 38% year-to-date.
The third quarter was especially hot. The Nasdaq Biotechnology Index rose 10% over that time frame and is up a healthy 37% this year.
And, nothing is hotter than companies focused on the battle against cancer.
Take Medivation Inc. (Nasdaq: MDVN), for example. This California-based biotech has jumped from $23 to $46 a share, largely on the approval of Xtandi, its novel prostate cancer drug.
Thousands of other experimental drugs are going through various stages of clinical trials, and the largest category in the pipeline is cancer drugs. With that in mind, it's safe to say that if you're looking for a stock with big upside potential, cancer-driven biotech stocks should be high on your list. Biotech Stocks: Cancer Research is Paying Off
A cancer diagnosis was once a death sentence -- especially if you were diagnosed with the disease in its late stages.
But, both government and industry have spent vast sums in the last decade researching how cancers develop and spread.
And now all that investment is starting to pay off -- recent clinical trials and treatment breakthroughs show real promise.
The newest cancer research focuses on three fronts.